Drug Pipeline News

Ritlecitinib could be a suitable treatment option for alopecia areata patients aged 12 years and older following positive results from a recent trial.

Roflumilast is a once-daily, topical phosphodiesterase type 4 (PDE4) inhibitor under development for treatment of inflammatory dermatoses, focusing on the hair-bearing areas including the face, scalp, and trunk.

Following voluntary market withdrawal from Covis Pharma, the FDA has decided to withdraw the approval of Makena and its generics for reducing the risk of preterm birth.

Data suggest confirmatory trials conducted for drugs granted accelerated approval by the FDA have taken a median 3.5 years to complete since 2012.

Leniolisib is the first and only treatment approved in the United States for APDS, a rare primary immunodeficiency.

Pediatric patients with BRAF V600E low-grade glioma as young as 1 year can now be treated with dabrafenib plus trametinib following its FDA approval.

Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.

A recent study indicated that lebrikizumab treatment for 16 weeks was effective for adolescents and adults with moderate-to-severe atopic dermatitis.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

If approved by the FDA, this 5-in-1 investigational candidate could provide the broadest meningococcal serogroup coverage.

The FDA has approved trofinetide (Daybue; Acadia Pharmaceuticals) for treating Rett syndrome in patients aged 2 years and older.

Covis, the manufacturer of the controversial preterm birth prevention drug Makena, has announced it will voluntarily withdraw the drug from the market after recommendations from the Center for Drug Evaluation and Research.

A supplemental New Drug Application for empagliflozin (Jardiance; Boehringer Ingelheim and Eli Lilly and Company) in pediatric patients with type 2 diabetes has been accepted by the FDA.

Following positive results from a phase 3 clinical trial, the FDA has accepted a New Drug Application for berdazimer gel, 10.3% (Novan) for treating patients with molluscum contagiosum.

A supplemental Biologics License Application has been accepted by the FDA for treating adolescents and adults with chronic spontaneous urticaria.

Velmanase alfa-tycv (Lamzede, Chiesi Global Rare Diseases) has received approval by the FDA for treating alpha-mannosidosis in adult and pediatric patients.

Omaveloxolone (SKYCLARYS, Reata Pharmaceuticals) has received FDA approval for treating Friedreich’s ataxia in patients aged 16 years and older.

The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.

A new drug application for VP-102 for treating molluscum contagiosum has been accepted by the FDA.

Previously known as efanesoctocog alfa, once-weekly ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes for adults and children with hemophilia A.

A New Drug Application has been submitted to the FDA for potential approval of roflumilast foam 0.3% for the treatment of seborrheic dermatitis in adults and adolescents.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

Read the latest medications for pediatric patients approved by the US Food and Drug Administration.

Linaclotide (LINZESS; Ironwood Pharmaceuticals) has been granted Priority Review by the US Food and Drug Administration for treating pediatric patients with functional constipation.

Aflibercept is now approved to treat 5 retinal conditions caused by ocular angiogenesis.

In a recent statement, the US Food and Drug Administration warned pharmacies and health care providers about unsafe aluminum levels for pediatric patients in Hospira’s unapproved potassium phosphates drug product.

A supplemental New Drug Application (sNDA) for abrocitinib (CIBINQO; Pfizer) in adolescents has been approved by the US Food and Drug Administration.

Lanadelumac (TAKHZYRO; Takeda) has received an approval for a supplemental Biologics License Application to prevent hereditary angioedema attacks in pediatric patients aged 2 years and older.

The US Food and Drug Administration has approved the use of a pre-filled tezepelumab (TEZSPIRE; Amgen and AstraZeneca) pen in patients aged 12 years and older with severe asthma.

Odactra (House Dust Mite Allergen Extract; ALK) has received approval from the US Food and Drug Administration for use in patients aged 12 to 17 years with house dust mite-induced allergic rhinitis.